LLY
Lilly(Eli) & Co
$1149.36-0.88%
Setup
No setup
Buy Zone
$1076.18-$1129.99
Sector
Drug Manufacturers - General
Industry
Drug Manufacturers - General
81
Recommendation
No setup
Hold
No active chart path confirmed. Keep on watchlist until price, volume, and setup align.
LLY chart
Loading chart…
ADX
Developing26.4Long Term
Up ↑Intermediate Term
Up ↑Short Term
Range →Overall Quality81
RS Rating
79
relative strength
Fundamentals
81
Strong fund-Q
Volume Demand
45
-23% vs avg
Technical Setup
38
3/8 checks
Industry/Theme
91
Drug Manufacturers - General
Trade Plan
No setup
Entry
$1076.18
Entry Zone
$1076.18-$1129.99
Stop / Risk
$990.09
RS Rating
79
Volume confirmed
No
Targets
$1291.42 / $1345.23
Breakout · IBD Setup
4 ✓ 4 ✗
Entry $1076.18–$1129.99Stop $990.09Target $1291.42 / $1345.23
Market regimeUptrend
Quality81
RS Rating79
Above 50-MA-3.54%
Above 200-MA+8.09%
VolumeWeak
In Buy ZoneNo
Not extendedOK
Invalidation · Close below stop
How this came together
81
MarketUptrend
SetupNo setup
ConfidenceExperimental · not backtested
Fund-Q81 · Strong
StatusHold
Stock Data
52-Week Range712 – 1293
Price % Chg YTD6.95%
Price % Chg 4wk-3.57%
50-Day Avg Vol2.9 Mil
P/E Ratio39.1
Market Cap$1.08T
SectorHealthcare
IndustryDrug Manufacturers - General
Company Fundamentals
EPS % Chg (Qtr)26.2%
Sales % Chg (Qtr)47.67%
EPS Growth 5y27.59%
Sales Growth 5y21.58%
Annual ROE102.43%
Gross Margin83.4%
Operating Margin49.72%
Net Margin33.53%
Debt / Equity1.62
Setup levels
Current price
$1149.36
Pivot
$1076.18
Distance to buy
-11.1%
52-week range
712.03-1292.58
Trigger evidence
No active trigger evidence available.
Financial health checks
4/5
Return on equity above 15%
ROE 102.43%
Net margin above 10%
Net margin 33.53%
EPS growing quarter on quarter
EPS q/q 26.2%
Sales growing quarter on quarter
Sales q/q 47.67%
Debt to equity below 1.0
D/E 1.62
Key metrics
Finviz snapshot · value vs. sector median (≥5 peers)
Annual ROE102.43%
vs sector +80.3%
Net margin33.53%
vs sector +16.5%
Gross margin83.4%
vs sector +16.7%
EPS growth q/q26.2%
vs sector +18.2%
Sales growth q/q47.67%
vs sector +29.1%
Debt / equity1.62
vs sector +0.98
Business quality
81
GradeStrong
EPS rating59
P/E39.1
Market cap$1.08T
IndustryDrug Manufacturers - General
Technical checks
Über 50-MA
Fail
Über 200-MA
Pass
RS-Linie auf neuem Hoch
Fail
Volumen bestätigt
Fail
In Kaufzone
Fail
Nicht überextended
Pass
Über 21-EMA
Fail
Volumen gesund
Pass
IBD / source mentions
No recent IBD mention found for this ticker.
Signal history
Added to list
2026-09-01
Trigger date
—
Days on list
6
Data sources: internal CANSLIM engine · Finviz snapshot · TradingView chart. Not investment advice.